Evidence mapPaperPMID 31964162Full record

ArticleThe American journal of psychiatry2020

U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001-2002 and 2012-2013.

Deborah S Hasin, Dvora Shmulewitz, Magdalena Cerdá, Katherine M Keyes, Mark Olfson, Aaron L Sarvet, Melanie M Wall

Erratum issuedAbstract read
In one paragraph

Article in The American journal of psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Interactions between cannabis use and chronic pain on sleep architecture: Findings from in-home EEG recordings.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Deborah S HasinNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Dvora ShmulewitzNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Magdalena CerdáNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Katherine M KeyesNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Mark OlfsonNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Aaron L SarvetNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Melanie M WallNew York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).

Funding

TRAINING IN PSYCHIATRIC EPIDEMIOLOGY/BIOSTATISTICST32MH017119 · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · 1985 to 2005
$3.0M
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DEBORAH S HASIN · 2023 to 2023
$746k
NIDA NIH HHS R01 DA019606NIDA NIH HHS R01 DA034244NIDA NIH HHS R01 DA048860NIMH NIH HHS T32 MH017119
6 · The paper itself

Abstract

objectiveGiven changes in U.S. marijuana laws, attitudes, and use patterns, individuals with pain may be an emerging group at risk for nonmedical cannabis use and cannabis use disorder. The authors examined differences in the prevalence of nonmedical cannabis use and cannabis use disorder among U.S. adults with and without pain, as well as whether these differences widened over time.

methodsData from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, 2001-2002; N=43,093) and NESARC-III (2012-2013; N=36,309) were analyzed using logistic regression. Risk differences of past-year nonmedical cannabis use, frequent (at least three times a week) nonmedical use, and DSM-IV cannabis use disorder were estimated for groups with and without moderate to severe pain, and these risk differences were tested for change over time.

resultsAny nonmedical cannabis use was more prevalent in respondents with than without pain (2001-2002: 5.15% compared with 3.74%; 2012-2013: 12.42% compared with 9.02%), a risk difference significantly greater in the 2012-2013 data than in the 2001-2002 data. The prevalence of frequent nonmedical cannabis use did not differ by pain status in the 2001-2002 survey, but was significantly more prevalent in those with than without pain in the 2012-2013 survey (5.03% compared with 3.45%). Cannabis use disorder was more prevalent in respondents with than without pain (2001-2002: 1.77% compared with 1.35%; 2012-2013: 4.18% compared with 2.74%), a significantly greater risk difference in the data from 2012-2013 than from 2001-2002.

conclusionsThe results suggest that adults with pain are a group increasingly vulnerable to adverse cannabis use outcomes, warranting clinical and public health attention to this risk. Psychiatrists and other health care providers treating patients with pain should monitor such patients for signs and symptoms of cannabis use disorder.

Indexed as

AdolescentAdultAgedCase-Control StudiesComorbidityFemaleHumansMaleMarijuana AbuseMarijuana SmokingMiddle AgedPainPrevalenceUnited StatesYoung AdultCannabisCannabis Use DisorderMarijuana Use EpidemiologyPainTime Trends

Identifiers

PMID31964162
PMCPMC7332392

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.